Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc is experiencing an increased probability of approval for its product candidate KYV-101, specifically for myasthenia gravis (MG), which has been raised to 35% from 25% due to its notable efficacy and safety indicators observed in patient trials. There is rising confidence in the long-term prospects of KYV-101, bolstered by its demonstrated durability and rapid response rates in initial treatments, as well as promising data from trials related to refractory rheumatoid arthritis (RA) and multiple sclerosis (MS). The ongoing positive developments and strong performance metrics for KYV-101 position it favorably in the competitive landscape of cell therapies for autoimmune diseases.

Bears say

Kyverna Therapeutics faces significant challenges that contribute to a negative outlook on its stock, primarily related to the efficacy of its lead product, KYV-101. Key concerns include the lack of durable responses in patients with lupus nephritis and myasthenia gravis, as indicated by the maturation of the current dataset, as well as uncertainty regarding positive outcomes for KYV-101 in other indications like systemic pemphigus. Additionally, the potential for long-term dilution risks further complicates the financial outlook for the company, raising questions about its future viability in the competitive biopharmaceutical market.

KYTX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 3 analysts, KYTX has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.